Drug Accountability in Clinical Trials: CFR 312 Compliance
This paper examines a drug accountability failure discovered during a clinical trial closeout visit, in which ten investigational pills were found to be unaccounted for. Drawing on 21 CFR 312.57 and 312.59, the paper outlines the federal regulatory obligations sponsors bear for tracking, returning, or disposing of investigational drugs. It then identifies best practices for preventing similar incidents, including designated handling personnel, rigorous record-keeping with batch and serial numbers, secure storage protocols, and an organizational culture of accountability. The analysis demonstrates that comprehensive documentation and trained personnel at every stage of drug handling are essential to good clinical practice compliance.
- Investigational Product Accountability and the Closeout Visit: Defines the missing-pill accountability problem
- Federal Regulatory Framework: 21 CFR 312.57 and 312.59: Outlines sponsor obligations under federal regulations
- Organizational Culture and Training as Preventive Measures: Cultural and training strategies to prevent loss
- Functional Best Practices for Drug Handling and Record-Keeping: Procedural controls for tracking drug movements
- Secure Storage and Inventory Control: Storage access rules and inventory monitoring
- Conclusion: Links better documentation to lower risk
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Grounds every claim in specific federal regulations (21 CFR 312.57 and 312.59), lending the analysis legal credibility.
- Moves logically from problem identification, to regulatory obligation, to preventive solutions — giving the argument a clear, actionable arc.
- Balances cultural/organizational recommendations with concrete procedural steps, addressing both root causes and operational fixes.
Key academic technique demonstrated
The paper demonstrates regulatory analysis applied to a case scenario: it cites the applicable Code of Federal Regulations provisions verbatim, interprets their requirements, and then maps those requirements onto a specific compliance failure. This technique — cite, interpret, apply — is the foundation of legal and regulatory writing in clinical research contexts.
Structure breakdown
The paper opens by defining the accountability problem, then establishes the regulatory basis for why it matters. Two separate solution-focused sections follow — one addressing culture and training, another addressing procedural and physical controls — before a brief conclusion ties risk-reduction back to documentation quality. The structure mirrors a standard compliance analysis report.
Investigational Product Accountability and the Closeout Visit
The failure of drug accountability in a clinical trial is a serious concern. One of the purposes of a closeout visit is to confirm that all investigational product is accounted for. When ten pills are missing, that standard has not been met. Unused supplies must be destroyed or returned, and in either case a complete accounting is required. Whatever happened to these ten pills should have been recorded, and since apparently it was not, nobody knows what became of them.
Federal Regulatory Framework: 21 CFR 312.57 and 312.59
This situation is governed by 21 CFR 312, which establishes the sponsor's obligations for investigational drug management. Specifically, 21 CFR 312.57 states that "a sponsor shall maintain adequate records showing the receipt, shipment or other disposition of the investigational drug." Furthermore, 21 CFR 312.59 states that "the sponsor shall assure the return of all unused supplies of the investigational drug from each individual investigator whose participation in the investigation is discontinued or terminated." Additional provisions govern the further disposition of the drug after return.
These requirements are all part of good clinical practice. The rules regarding the closeout visit and the accounting of each pill are unequivocal. As a result, there is no question that the ten missing pills represent a compliance problem. There is a clear responsibility to determine what happened to those pills, why no paperwork was filed on them, and who bears responsibility for this incident.
Create your account
Always verify citation format against your institution’s current style guide requirements.